Difference between revisions of "Team:BostonU"
| Line 286: | Line 286: | ||
<div class="fade-in-div"> <a class="wordmark" href="https://2017.igem.org/Team:BostonU"><img src="https://static.igem.org/mediawiki/2017/f/f2/T--BostonU--RedGrey.svg"></img></a> | <div class="fade-in-div"> <a class="wordmark" href="https://2017.igem.org/Team:BostonU"><img src="https://static.igem.org/mediawiki/2017/f/f2/T--BostonU--RedGrey.svg"></img></a> | ||
<section id="fade-in-wrapper" class="link-slideup body-type"> | <section id="fade-in-wrapper" class="link-slideup body-type"> | ||
| − | <p>We explore the use of de novo designed riboriboregulators known as <a href="#">toehold switches</a> to drive recombinase-based logic in <a href="#">cell-free TX-TL systems.</a> We anticipate applications in <a href="#">point-of-care diagnostic technologies</a> such as those for Zika and Ebola developed by the Collins group at MIT, targeted at diseases with RNA profiles that are more computationally demanding, such as cancer.</p> | + | <p class="body-type">We explore the use of de novo designed riboriboregulators known as <a href="#">toehold switches</a> to drive recombinase-based logic in <a href="#">cell-free TX-TL systems.</a> We anticipate applications in <a href="#">point-of-care diagnostic technologies</a> such as those for Zika and Ebola developed by the Collins group at MIT, targeted at diseases with RNA profiles that are more computationally demanding, such as cancer.</p> |
</section> | </section> | ||
<div id="fade-in-footer"> | <div id="fade-in-footer"> | ||
Revision as of 21:12, 18 October 2017
